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Abstract 
Contemporary medical therapy consists of treating all the patient’s modifiable vascular risk 
factors and instituting therapy designed to reduce the risk of thrombosis and the progression 
of atherosclerosis in order to reduce the risk of future cardiovascular events. Contemporary 
medical management emphasises the need to support the patient in achieving life-style 
modifications and to adjust medication to achieve individualised target values for specific 
quantifiable risk factors. Antiplatelet therapy in the form of aspirin or clopidogrel is routinely 
used for the prevention of ischaemic stroke in patients who have had a TIA or stroke. There is 
evidence from a recent trial that the use of combination antiplatelet therapy with aspirin and 
clopidogrel started within 24 hours of minor stroke or TIA reduces the risk of recurrent stroke 
compared to the use of aspirin alone and we therefore use aspirin plus clopidogrel in recently 
symptomatic patients with carotid stenosis pending carotid revascularisation. Anticoagulation 
with heparins or vitamin K antagonist is not recommended except in patients at risk for 
cardio-embolic events. Lowering blood pressure to target levels has been shown to slow 
down the progression of carotid artery stenosis and reduces the intima-media thickness of the 
carotid plaque, while lowering lipid levels with statins has become an essential element in the 
medical therapy of carotid artery stenosis. Diabetes management should be optimised. 
Lifestyle choices including tobacco smoking, physical inactivity, unhealthy diet, obesity, and 
excessive alcohol intake, are all important modifiable vascular risk factors. The combination 
of dietary modification, physical exercise, and the use of aspirin, a statin and an 
antihypertensive agent can be expected to give a cumulative relative stroke risk reduction of 
80%. The evidence suggests that intensive medical therapy is so effective that carotid 
revascularisation may no longer be necessary in many of the patients in whom carotid surgery 
or stenting is currently performed. Two large on-going trials are therefore comparing the risks 
and benefits of carotid revascularisation versus intensive medical therapy alone. 
 
Introduction 
Medical management plays an important role in the prevention of ischaemic stroke and other 
cardiovascular diseases in patients with atherosclerotic carotid artery disease. Optimising the 
management for each individual can be challenging, but small changes in therapy can 
substantially reduce the risk of recurrent ischaemic stroke. Therefore, it is important that 
every patient found to have carotid atherosclerosis has an individualised optimum 
management plan instituted to lower the risk of stroke. This chapter will describe the current 
concept of modern medical therapy in carotid artery disease in four different sections: the 
content of medical therapy, the evidence supporting the effect of medication and life style 
changes, the current recommendations in three different guidelines, and ongoing clinical 
trials regarding this topic.  
Contemporary medical therapy consists of treating all the patient’s modifiable vascular risk 
factors and instituting therapy designed to reduce the risk of thrombosis and the progression 
of atherosclerosis in order to reduce the risk of future cardiovascular events.1,2 The main 
modifiable factors accounting for the development of atherosclerosis in the carotid artery are 
hypertension, diabetes mellitus, dyslipidaemia, obesity and smoking.3 Anti-thrombotic 
therapy reduces the risk of embolization of the carotid plaque and is also considered an 
important component of medical therapy in carotid stenosis.4  
In the past, there was a tendency for physicians to recommend life style changes and drug 
treatment for vascular risk factors without closely monitoring the patient’s compliance or 
response to treatment.  However, contemporary medical management emphasises the need to 
support the patient in achieving life-style modifications and to adjust medication to achieve 
individualised target values for specific quantifiable risk factors e.g. hypertension. The 
success of this approach of intensive or so-called ‘aggressive’ management of vascular risk 
factors is best exemplified by the results of the Stenting and Aggressive Medical 
Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial.5,6 
In this trial, patients with recent transient ischaemic attack (TIA) or stroke related to 70–99% 
intracranial stenosis secondary to atherosclerosis were randomly allocated to intracranial 
stenting with intensive medical therapy with versus aggressive medical therapy alone. 
Aggressive medical therapy included dual antiplatelet therapy with aspirin and clopidogrel 
for 90 days after randomisation, antihypertensive medication adjusted to achieve a systolic 
blood pressure lower than 140 mmHg, and statin therapy to achieve a low-density lipoprotein 
cholesterol target less than 1·81 mmol/L, with repeated advice on smoking, weight control, 
and exercise. In the group of patients receiving medical therapy alone, a much lower stroke 
rate occurred compared to a previous study done by the same group of investigators in similar 
patients. In the earlier trial, the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) 
trial,7 a 30-day rate of stroke or death of 10.7% with a 1-year rate of 25% was recorded with 
medical therapy alone. In SAMMPRIS, patients randomised to aggressive medical therapy 
alone had roughly half the rates of events as in the earlier trial with a 30-day rate of stroke or 
death of 5.8% and a 1-year rate of 12.2%.  It is likely that similar benefits could be achieved 
with intensive treatment regimes in patients with atherosclerosis at other sites, including the 
carotid artery. 
The evidence for the benefits of medical therapy in carotid artery disease 
Medical therapy for carotid stenosis has improved over time, with more understanding of the 
effect of antithrombotic medication on the prevention of cardiovascular diseases, lower 
targets for blood pressure control and the addition of statins to the medical therapy. The 
literature has multiple conducted clinical trials in this topic and the evidence is growing 
progressively. 
Antiplatelet therapy in the form of aspirin or clopidogrel is routinely used for the prevention 
of ischaemic stroke in patients who have had a TIA or stroke. The combination of 
dipyridamole and aspirin is sometimes used as an alternative. The clinical trial known as 
PRoFESS conducted by Sacco et al.8 showed that the effect of clopidogrel alone in on the 
rates of recurrent stroke is similar to the combination of aspirin with dipyridamole in patients 
with pervious stroke. Similarly, the MATCH study showed when treatment was started at a 
mean of 27 days after stroke or TIA, the combination of aspirin and clopidogrel was not 
superior to clopidogrel alone, and had a higher risk of a major bleeding with the addition of 
aspirin.9 In contrast, in the CHANCE study when combination antiplatelet therapy was 
started within 24 hours of minor stroke or TIA and continued for 21 days, combined aspirin 
and clopidogrel reduced significantly reduced the risk of recurrent stroke compared to the use 
of aspirin alone.10,11 Dual antiplatelet with low-dose aspirin and clopidogrel has also been 
shown to be beneficial in coronary heart disease.12-14 However, current guidelines for the 
treatment of acute stroke and TIA do not seem to have kept up with this evidence, and most 
still recommended either aspirin alone, aspirin with dipyridamole, or clopidogrel alone. No 
large trials have examined the individual benefits of antiplatelet therapy specifically in 
patients with carotid disease. However, we use the combination of aspirin plus clopidogrel in 
patients with acute minor stroke and TIA pending carotid revascularisation, as long as the 
patient does not have an increased risk of bleeding.  This combination is then continued for 
up to 3 months after revascularisation, especially in patients who have had carotid stenting. 
Antiplatelet therapy seems not to be effective in preventing cerebral ischaemic events in 
patients with asymptomatic carotid stenosis, but only one randomised trial has specifically 
examined this indication.15 However, antiplatelet therapy is currently recommended in these 
patients to prevent myocardial infarction.  
Unfractioned heparin or low-molecular-weight heparin is not recommended as routine 
treatment to prevent recurrent stroke because several trials have shown no benefit in the acute 
situation compared to aspirin therapy. Similarly, oral anticoagulation with vitamin K 
antagonist is also not recommended in patient with stroke or TIA of non-cardiac origin 
because trials have shown that anticoagulation is not superior to aspirin in the prevention of 
long-term stroke recurrence and carries a substantial risk of haemorrhage.16 Vitamin K 
antagonists are only recommended in patients at risk for cardio-embolic events e.g. those 
with atrial fibrillation.17  
The management of blood pressure has also improved over the last few years due to the 
availability of different types of anti-hypertensives to achieve lower target blood pressure 
levels in individuals. Lowering the blood pressure to target levels is shown to slow down the 
progression of carotid artery stenosis and reduces the intima-media thickness of the carotid 
plaque.18,19 However, it is important to manage the blood pressure at a proper range as a too 
low blood pressure of <110/70 mmHg and a too high blood pressure of >140/90 mmHg are 
also associated with stroke.20  
Lowering lipid levels with statins has become an essential element in the medical therapy of 
carotid artery stenosis. This was evident after the publication of the Stroke Prevention by 
Aggressive Reduction in Cholesterol Levels (SPARCL) trial21, which randomly allocated 
patients with recent stroke or TIA to a high dose of atorvastatin versus placebo. Patients 
receiving atorvastatin had a reduction of future stroke risk of 16%.21 According to a 
systematic review, this effect is mainly caused by the reduction of LDL-cholesterol.22 In 
addition, the use of statins can evidently improve carotid atherosclerosis by inducing a 
decrease in plaque inflammation and size and slowing down the progression of the 
atherosclerotic disease.23,24  
Diabetes is strongly associated with the development of atherosclerosis in the carotid artery,25 
and also increases the risk of stroke.26,27 A recent cross-sectional study of 1475 persons 
randomly selected from a normal population, has shown that the glycaemic status is 
associated with the presence of carotid atherosclerosis.28 The prevalence of significant carotid 
stenosis of the persons previously diagnosed with diabetes mellitus was 7.7% in this group, 
compared to 0.3% in persons with a normal glucose tolerance. Several studies have shown 
that antidiabetic medication slows the progression and regresses carotid atherosclerosis.29,30 
Lifestyle choices including tobacco smoking, physical inactivity, unhealthy diet, obesity, and 
excessive alcohol intake, are all important modifiable vascular risk factors. Tobacco smoking 
for instance, increases the relative risk of ischaemic stroke by up to 50%.31 A quantitative 
modeling study based on a comprehensive review of the meta-analyses of the effect of 
combined secondary prevention strategies conducted by Hackam and Spence, concluded that 
the combination of dietary modification, physical exercise, and the use of aspirin, a statin and 
an antihypertensive agent could give a cumulative relative stroke risk reduction of 80%.32 
The authors reported that the lifestyle risk factor with the largest impact on future stroke is a 
change in the diet, reducing the risk by 44%, but the review did not take weight loss or the 
effects of reducing alcohol intake into account. However, it is possible that the benefit of 
changes in diet was achieved by weight loss rather than the components of a healthy diet. Not 
many studies have reported the effect of changes in body weight on the risk of cardiovascular 
events. In practice, it is not only difficult to modify a patient’s diet, but it is also relevant that 
any change in the diet (a reduction of saturated fats or a reduction of total energy 
consumption) does not result in a large reduction in cholesterol levels compared to statin 
therapy.  
It is well known that obesity is associated with a higher risk of developing diabetes mellitus,33 
but it is also known that obesity can induce hypertension.34 Both diabetes and hypertension 
are risk factors for the development of atherosclerosis and therefore maintaining a normal 
weight should be encouraged in patients with carotid artery stenosis. Heavy alcohol intake of 
more than 5 units or more than 60 gram per day is associated with an increased risk of stroke 
of any type.35 The same study also showed that light intake of alcohol of 1-2 units or 12-24 
gram per day is associated with a lower risk of ischaemic stroke. Changing the five lifestyle 
choices of smoking cessation, physical exercise, healthy diet, maintaining a healthy weight, 
and alcohol consumption are clearly just as important as medical treatment to reduce the risk 
of stroke in patients with carotid artery disease. 
 
Current guidelines for medical therapy of carotid artery disease 
There have been several guidelines published in this topic, all of which are described in a 
recent systematic review.36 This review included 34 guidelines from 23 different regions or 
countries and concluded that there are many weaknesses in the guidelines in terms of the 
accessibility of the guidelines, and the representation of the relevant evidence. This chapter 
will discuss three currently accepted guidelines, one representing the United States reported 
by the American Stroke Association (ASA) and American College of Cardiology Foundation 
(ACCF) and 12 other societies,37 one representing Europe approved by the European Society 
for Vascular Surgery (ESVS),38 and the current National Institute for Health and Care 
Excellence (NICE) guidelines from the United Kingdom.48-52 The main difference between 
the NICE guidelines and the two other guidelines chosen is that the recommendations that we 
discuss from the NICE guidelines are aimed towards patients with individual vascular risk 
factors and do not deal specifically with carotid artery stenosis unlike the other two 
guidelines. Table 1 provides a summary of the main recommendations for medical therapy 
made in the three chosen guidelines with the level of evidence per recommendation cited in 
the corresponding publication. 
 
Anti-thrombotic therapy 
In the ASA/ACCF guideline, antiplatelet therapy in the form of aspirin alone is recommended 
in patients with carotid artery stenosis, regardless of whether the patient is symptomatic or 
asymptomatic. In contrast, the ESVS guideline recommends aspirin with dipyridamole as the 
first option in patients with symptomatic carotid stenosis, and clopidogrel alone as second 
option. The NICE guideline indicates that patients with ischaemic stroke should be advised to 
start clopidogrel. However, the NICE guideline is based on evidence that comes from 
randomised controlled trials of patients who experienced ischaemic stroke, and not patients 
with carotid artery stenosis. 
 
Blood pressure management 
It is generally recommended that the target clinic blood pressure value should be maintained 
to below 140/90 mmHg with antihypertensive medications in patients with asymptomatic 
carotid artery stenosis and hypertension. In the NICE hypertension guideline, higher target 
levels of 150/90 are specified for patients aged 80 years or older, while lower target levels of 
are specified for patients with diabetes and prior stroke or TIA or other risk factors of 
<130/80. In patients with symptomatic carotid stenosis, the relationship between blood 
pressure and the risk of further cerebral ischaemia has not been established and there has 
been concern that the lower targets might risk causing haemodynamic stroke in patients with 
severe carotid stenosis or occlusion. However, in our experience lowering blood pressure to 
these target values is safe even in patients with bilateral carotid disease, so long as the blood 
pressure is lowered slowly and severe hypotension is avoided. 
 
Controlling blood glucose levels in patients with diabetes mellitus 
The ASA/ACCF guideline states that there is no evidence that controlling blood glucose 
levels to achieve a level of glycosylated haemoglobin A1c (HbA1c) at or below 7% has a 
benefit in the prevention of ischaemic stroke. However, it is recommended that these patients 
should be prescribed a statin to lower the LDL-cholesterol to a level below 1.8 mmol/l (70 
mg/dl). No recommendations are made in the ESVS guideline regarding the control of blood 
glucose levels. In the NICE guidelines, recommendations are made for patients with DM with 
a target to lower HbA1c levels to 6.5%. 
 
Lipid lowering therapy 
Patients with carotid artery stenosis and hypercholesterolaemia are recommended treatment 
with statins to achieve a low-density lipoprotein (LDL) value below 2.6 mmol/l (100 mg/dl). 
In patients with a history of ischaemic stroke or TIA, it is reasonable to reduce the LDL-
cholesterol to a level near or below 1.8 mmol/l (70 mg/dl).  
 
Lifestyle changes 
In the ASA/ACCF guideline, only the cessation of tobacco smoking is recommended. In the 
ESVS and NICE guidelines, however, recommendations are also made for the intake of 
alcohol, weight reduction, and physical activity.   
 
When is medical management alone insufficient in carotid disease? 
Patients with symptomatic carotid stenosis have a much higher risk for future recurrent stroke 
compared to asymptomatic patients. The purpose of the medical therapy for the prevention of 
cardiovascular events are slightly different in these two groups of patients. In asymptomatic 
patients, the annual risk of stroke due to the carotid plaque is less than 1% according to a 
meta-analysis performed in 2009.39 The annual risk for death due to a non-stroke cause in 
these patients, are known to be higher than the risk of ipsilateral stroke. It is said that more 
than 50% of the non-stroke deaths are due to ischaemic heart disease.40 This suggests that 
asymptomatic carotid stenosis gives a better indication of atherosclerotic disease elsewhere in 
the body rather than indicating a particularly high risk of stroke.  
The effect of surgical intervention on the risk of stroke in patients with asymptomatic 
stenosis, was studied in one of the largest randomised controlled trials, the Asymptomatic 
Carotid Surgery Trial – 1 (ACST-1).41 In this trial, more than 3000 asymptomatic patients 
were randomised to immediate carotid endarterectomy (CEA) versus deferral of any carotid 
surgical intervention. CEA caused some risk of perioperative stroke or death, but immediate 
CEA almost halved the non-perioperative stroke rate over the next 10 years (10.0% risk of 
non-perioperative stroke in the immediate CEA group compared to 4.1% in the deferral of 
CEA group at 5 years, with 16.9% compared to 10.8% at 10 years respectively). Due to this 
small reduction of the risk in patients who underwent direct surgical intervention, studies are 
trying to identify the high risk group in the group of patients with asymptomatic carotid 
stenosis. Current guidelines suggest that surgical intervention is reasonable in patients with 
high-grade asymptomatic carotid artery stenosis (see table 2), but many experts do not refer 
asymptomatic stenosis for surgery, preferring intensive medical therapy alone as we have 
outlined above. 
Symptomatic patients have a much higher risk for future recurrent stroke compared to 
asymptomatic patients. In the Oxford Vascular Study (OXVASC), it was shown that the risk 
of recurrent ipsilateral stroke is 27% during the first 30 days after a TIA or minor stroke in 
patients with symptomatic carotid stenosis of more than 50%.42 This risk is much higher 
compared to the 1-year risk of stroke of less than 1% in asymptomatic patients. Therefore it is 
recommended for patients with high-grade symptomatic stenosis of 70-99% to undergo CEA. 
CEA was shown to be highly beneficial in reducing this high risk with medical therapy in 
patients with high-grade symptomatic stenosis of 70-99% in the original CEA trials.43 The 
absolute risk reduction of this group was 16.0%. The same review suggest that symptomatic 
patients with 50-69% stenosis have some benefit of CEA, with an absolute risk reduction of 
4.6%. Table 2 provides a summary of the recommendations for surgical intervention 
according to the ASA/ACCF37 and ESVS guidelines.44 
 
Current ongoing trials in the management of carotid artery disease 
The evidence discussed above suggests that intensive medical therapy is so effective that 
carotid revascularisation may no longer be necessary in many of the patients in whom carotid 
surgery or stenting is currently performed. The current guidelines are based on trials done 
more than 20 years ago and thus these trials need to be repeated using current intensive 
medical therapy regimes at least in patients who are not in the highest risk categories. Two 
large on-going trials are therefore comparing the risks and benefits of carotid 
revascularisation versus intensive medical therapy alone. The European Carotid Surgery Trial 
2 (ECST-2)45 and the Carotid Revascularisation and Medical Management for Asymptomatic 
Carotid Stenosis Trial (CREST-2)46 are both investigating the outcome of patients with 
carotid surgery comparing carotid revascularisation together with current medical therapy 
versus medical therapy alone in patients with carotid artery stenosis.. 
ECST-2 is a multicentre, prospective, randomised clinical trial of patients with both 
symptomatic and asymptomatic carotid artery stenosis, which started recruitment in 2012. 
The patients in this trial are selected on the basis of the Carotid Artery Risk (CAR) score,47 
which is used to predict the 5-year risk of ipsilateral stroke of patients with carotid artery 
stenosis. Patients with a 5-year risk of less than 20% are then randomly allocated optimised 
medical therapy alone or optimised medical therapy with the addition of immediate carotid 
revascularisation, which is either carotid endarterectomy or carotid stenting according to the 
preference of the clinicians. Both symptomatic and asymptomatic patients can be enrolled in 
this trial and the primary outcome is stroke at any time after enrolment and non-stroke death 
occurring within 30 days of revascularisation. The follow up duration will be a minimum of 5 
years up to a maximum of 10 years. This study is unique due to the use of a clinical risk 
prediction model to select and exclude patients, dividing patients into a low, intermediate, 
and high risk score for ipsilateral recurrent stroke, the latter being excluded and 
recommended for immediate revascularisation.  
CREST-2 consists of two randomised controlled trials, and has been randomising patients 
with asymptomatic high-grade carotid stenosis since 2014. Patients are randomised to carotid 
revascularisation and intensive medical management or medical management. One of the two 
trials randomises patients to carotid endarterectomy versus no surgical intervention, the other 
trial randomly allocates patients to carotid stenting with embolic protection versus no surgical 
intervention. Patients randomised to this trial have to have asymptomatic carotid stenosis 
measuring 70% or more in severity. Patients are excluded if they are symptomatic on the 
ipsilateral side of the carotid stenosis within the last 180 days of randomisation. The primary 
outcome is ipsilateral stroke, stroke during revascularisation or death at 30 days. The follow 
up duration is 4 years.  
 
Conclusion 
Medical therapy for carotid artery stenosis for the primary and secondary prevention of 
ischaemic stroke is important and consists of treating several risk factors, including lifestyle 
modifications. The risk of ipsilateral stroke is different in symptomatic and asymptomatic 
patients and the purpose of medical treatment is therefore slightly different. Two guidelines 
from two large groups representing the US and Europe have similar recommendations for 
patients with carotid artery stenosis. For patients with carotid artery disease with a moderate 
risk of recurrent stroke, and for asymptomatic high-grade stenosis it is still the question 
whether surgical intervention with medical therapy or medical therapy alone is superior. 
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